HORSHAM, PA — STRATA Skin Sciences Inc. (NASDAQ: SSKN) said a February 2026 systematic review and meta-analysis published in the Journal of Drugs in Dermatology found that 308 nm excimer laser therapy was associated with significant improvements in plaque psoriasis.
The analysis, conducted by investigators from Georgetown University School of Medicine and MedStar Washington Hospital Center, reviewed clinical trials evaluating the efficacy of 308 nm excimer laser treatment for plaque psoriasis.
Across the included studies, patients were generally treated twice weekly for at least 10 sessions, with outcomes measured using the Psoriasis Area and Severity Index, or PASI.
According to the publication, PASI scores declined significantly in multiple studies. In a trial by Tang et al. involving 32 patients, PASI improved from 11.47 to 5.08. In a study by He et al. of 40 patients, PASI improved from 14.73 to 2.42. Gerber et al., in a study of 100 patients, reported a reduction from 13.70 to 2.10, and Dong et al., in a study of 20 patients, reported a decline from 12.02 to 4.09.
Patients in the reviewed studies typically achieved results within 10 to 14 treatments over approximately five to seven weeks, the company said.
The publication also examined minimal erythema dose-guided dosing, a method used to determine the lowest ultraviolet B exposure that produces visible skin redness after 24 hours.
Treatment fluences in the reviewed studies generally ranged from about 200 to 600 millijoules per square centimeter per session, with some protocols using higher levels, according to the analysis.
“This meta-analysis reinforces what dermatologists have observed clinically — that properly calibrated, MED-guided Excimer Laser therapy provides effective, targeted treatment for plaque psoriasis,” said Dr. Dolev Rafaeli, chief executive officer of STRATA Skin Sciences.
STRATA said its XTRAC technology platform is designed to deliver targeted 308 nm ultraviolet B doses to affected areas.
The study, titled “Excimer Laser for Plaque Psoriasis: A Systematic Review and Meta-analysis,” was published in the February 2026 issue of the Journal of Drugs in Dermatology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.